Locations:
Search
Investigators working with FDA on safety signal
Drug targets CD33 to produce high remission rates
Two smaller sequential doses may be better than one
Interim analysis signals efficacy in older patients
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Findings may help guide risk-adapted thromboprophylaxis
Findings may help individualize care and optimize patient well-being.
Cleveland Clinic’s pilot study signals efficacy in HHT
Trial results reported for first molecularly targeted therapy
Please join our staff as we participate or present in the following oral and poster presentations at the 2016 ASH Annual Meeting
Patented CCF642 shows efficacy in mouse myeloma model
Advertisement
Advertisement